News

KBio Announces FDA Clearance of IND Application for EV68-228-N for the Treatment of Acute Flaccid Myelitis and the First Patient Dosed in the Phase 1 Study
June 28, 2024

LONDON, June 28, 2024 – KBio, one of the leading developers of new biological treatments derived from a plant-based production […]
KBio and ZERO Announce Exclusive Strategic Alliance to Develop a Globally Distributed and Rapidly Deployable Plant-Based Molecular Farming Network
August 1, 2023

WORLD’S FIRST GLOBALLY DISTRIBUTED AND RAPIDLY DEPLOYABLE PLANT-BASED MOLECULAR FARMING NETWORK TO INCLUDE THERAPEUTIC, PANDEMIC PREPAREDNESS AND BIOACTIVE INGREDIENT PRODUCTION […]
KBio Announces Strategic Collaboration with Leaf Expression Systems to Enhance Development and Production of Novel Therapeutics
September 28, 2022

LONDON — September 28, 2022— KBio, a leading developer of new biological treatments derived from a plant-based production system, today […]
KBio Announces Strategic Partnership with ZabBio to Discover and Develop Antibody Therapeutics
September 13, 2022

LONDON and SAN DIEGO— September 12, 2022—KBio, a leading developer of new biological treatments derived from a plant-based production system, […]
KBio Appoints Sean Stevens, Ph.D. as Chief Scientific Officer
May 5, 2022

LONDON, May 05, 2022 — KBio, a leading developer of new biological treatments derived from a plant-based production system, today […]
BAT creates biotech company KBio to accelerate development of existing plant-based technology
January 7, 2022

BAT today announced the launch of KBio Holdings Limited (KBio) to accelerate the research, development and production of novel treatments. […]

KBio Inc is a wholly owned subsidiary of KBio Holdings Limited, a BAT Group company.

Scroll to Top